Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- 1 June 2018
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 173 (7), 1770-1782.e14
- https://doi.org/10.1016/j.cell.2018.04.034
Abstract
No abstract availableKeywords
Funding Information
- Prostate Cancer Foundation
- StandUp2 Cancer
- Prostate Cancer Foundation Prostate Dream Team (SU2C-AACR-DT0712)
- Department of Defense (W81XWH-15-1-0562)
- Early Detection Research Network (U01 CA214170)
- Prostate SPORE (P50 CA186786, P50 CA097186)
- PCF Young Investigator Grant
- DOD Prostate Cancer Research Program Idea Development Award (PC160429)
This publication has 69 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Genes & Development, 2010
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences of the United States of America, 2007
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005